579 related articles for article (PubMed ID: 24390336)
1. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
[TBL] [Abstract][Full Text] [Related]
2. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
[TBL] [Abstract][Full Text] [Related]
3. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
Perdiguero B; Gómez CE; Nájera JL; Sorzano CO; Delaloye J; González-Sanz R; Jiménez V; Roger T; Calandra T; Pantaleo G; Esteban M
PLoS One; 2012; 7(10):e48524. PubMed ID: 23119046
[TBL] [Abstract][Full Text] [Related]
4. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
García-Arriaza J; Nájera JL; Gómez CE; Sorzano CO; Esteban M
PLoS One; 2010 Aug; 5(8):e12395. PubMed ID: 20811493
[TBL] [Abstract][Full Text] [Related]
6. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
7. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
[TBL] [Abstract][Full Text] [Related]
8. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
[TBL] [Abstract][Full Text] [Related]
9. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
10. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
11. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
12. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
13. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
[TBL] [Abstract][Full Text] [Related]
14. Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B.
Pérez P; Marín MQ; Lázaro-Frías A; Sorzano CÓS; Gómez CE; Esteban M; García-Arriaza J
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32041218
[TBL] [Abstract][Full Text] [Related]
15. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
Gómez CE; Nájera JL; Perdiguero B; García-Arriaza J; Sorzano CO; Jiménez V; González-Sanz R; Jiménez JL; Muñoz-Fernández MA; López Bernaldo de Quirós JC; Guardo AC; García F; Gatell JM; Plana M; Esteban M
J Virol; 2011 Nov; 85(21):11468-78. PubMed ID: 21865377
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.
Perdiguero B; Gómez CE; Di Pilato M; Sorzano CO; Delaloye J; Roger T; Calandra T; Pantaleo G; Esteban M
PLoS One; 2013; 8(9):e74831. PubMed ID: 24069354
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
[TBL] [Abstract][Full Text] [Related]
18. Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene
Chea LS; Wyatt LS; Gangadhara S; Moss B; Amara RR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541829
[TBL] [Abstract][Full Text] [Related]
19. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
[TBL] [Abstract][Full Text] [Related]
20. Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.
Garber DA; O'Mara LA; Gangadhara S; McQuoid M; Zhang X; Zheng R; Gill K; Verma M; Yu T; Johnson B; Li B; Derdeyn CA; Ibegbu C; Altman JD; Hunter E; Feinberg MB
J Virol; 2012 Dec; 86(23):12605-15. PubMed ID: 22973033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
